Q3 2025 Holdings
Filed 2025-11-14 | 46 holdings | $2.5B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $311.5M | 5,502,710 | 12.6% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $185.6M | 3,974,913 | 7.5% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $170.1M | 2,560,916 | 6.9% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $141.6M | 19,751,284 | 5.7% |
| Cidara Therapeutics Inc(CDTX) | COM NEW | 171757206 | $135.4M | 1,414,165 | 5.5% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $126.2M | 8,827,712 | 5.1% |
| Mirum Pharmaceuticals Inc(MIRM) | COM | 604749101 | $109.6M | 1,495,290 | 4.4% |
| Xoma Royalty Corporation(XOMA) | COM NEW | 98419J206 | $99.8M | 2,590,303 | 4.0% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $89.7M | 3,203,917 | 3.6% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $76.3M | 8,617,162 | 3.1% |
| Septerna Inc(SEPN) | COM | 81734D104 | $75.5M | 4,015,790 | 3.1% |
| Palvella Therapeutics Inc NE(PVLA) | COM | 697947109 | $72.8M | 1,161,249 | 3.0% |
| Nektar Therapeutics(NKTR) | COM NEW | 640268306 | $72.6M | 1,276,595 | 2.9% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $67.3M | 3,938,641 | 2.7% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $59.1M | 486,757 | 2.4% |
| AC Immune SA(ACIU) | SHS | H00263105 | $57.3M | 19,822,436 | 2.3% |
| Immunocore Hldgs PLC(IMCR) | ADS | 45258D105 | $57.2M | 1,574,288 | 2.3% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $51.8M | 5,295,893 | 2.1% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $51.1M | 3,649,794 | 2.1% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $47.4M | 558,031 | 1.9% |
| Monte Rosa Therapeutics Inc(GLUE) | COM | 61225M102 | $41.9M | 5,660,132 | 1.7% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $40.2M | 4,629,289 | 1.6% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $38.9M | 1,657,096 | 1.6% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $34.1M | 5,750,683 | 1.4% |
| Celcuity Inc(CELC) | COM | 15102K100 | $32.5M | 658,421 | 1.3% |
| Xencor Inc(XNCR) | COM | 98401F105 | $32.1M | 2,740,141 | 1.3% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $25.9M | 5,302,000 | 1.1% |
| Annexon Inc(ANNX) | COM | 03589W102 | $21.4M | 7,000,000 | 0.9% |
| Repare Therapeutics Inc(RPTX) | COM | 760273102 | $18.2M | 10,333,600 | 0.7% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $17.2M | 1,355,256 | 0.7% |
| Compass Therapeutics Inc(CMPX) | COM | 20454B104 | $16.6M | 4,750,000 | 0.7% |
| Crescent Biopharma Inc.(CBIO) | COM | G2545C104 | $16.5M | 1,387,863 | 0.7% |
| Eledon Pharmaceuticals Inc(ELDN) | COM | 28617K101 | $16.3M | 6,293,282 | 0.7% |
| Tscan Therapeutics Inc(TCRX) | COM | 89854M101 | $9.5M | 5,226,074 | 0.4% |
| Pepgen Inc(PEPG) | COM | 713317105 | $8.8M | 1,915,000 | 0.4% |
| X4 Pharmaceuticals Inc(XFOR) | COM NEW | 98420X202 | $7.6M | 2,233,742 | 0.3% |
| Immunic Inc(IMUX) | COM | 4525EP101 | $6.7M | 7,652,972 | 0.3% |
| Imagenebio Inc(IMA) | COM | 45175G207 | $6.5M | 802,102 | 0.3% |
| Molecular Partners AG(MOLN) | ADS | 60853G106 | $5.0M | 1,353,968 | 0.2% |
| Inventiva SA(IVA) | ADS | 46124U107 | $4.0M | 686,040 | 0.2% |
| Tenax Therapeutics Inc(TENX) | COM NEW | 88032L605 | $2.6M | 339,549 | 0.1% |
| Essa Pharma Inc(EPIEUR) | COM NEW | 29668H708 | $2.2M | 11,668,473 | 0.1% |
| SAB Biotherapeutics Inc(SABS) | COM NEW | 78397T202 | $1.9M | 932,697 | 0.1% |
| Forte Biosciences Inc(FBRX) | COM NEW | 34962G208 | $980.3K | 65,350 | 0.0% |
| Engene Holdings Inc(ENGNW) | *W EXP 10/31/202 | 29286M113 | $680.7K | 945,402 | 0.0% |
| NLS Pharmaceutics LTD | COM NEW | H57830137 | $262.9K | 143,676 | 0.0% |